Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellectis (CLLS) Total Liabilities (2016 - 2025)

Cellectis has reported Total Liabilities over the past 12 years, most recently at $248.8 million for Q4 2025.

  • Quarterly results put Total Liabilities at $248.8 million for Q4 2025, down 1.46% from a year ago — trailing twelve months through Dec 2025 was $248.8 million (down 1.46% YoY), and the annual figure for FY2025 was $248.8 million, down 1.46%.
  • Total Liabilities for Q4 2025 was $248.8 million at Cellectis, down from $252.5 million in the prior quarter.
  • Over the last five years, Total Liabilities for CLLS hit a ceiling of $252.5 million in Q4 2024 and a floor of $131.1 million in Q2 2023.
  • Median Total Liabilities over the past 5 years was $145.6 million (2021), compared with a mean of $185.2 million.
  • Biggest five-year swings in Total Liabilities: decreased 9.35% in 2021 and later soared 84.49% in 2023.
  • Cellectis' Total Liabilities stood at $145.6 million in 2021, then dropped by 7.09% to $135.3 million in 2022, then soared by 84.49% to $249.6 million in 2023, then grew by 1.18% to $252.5 million in 2024, then fell by 1.46% to $248.8 million in 2025.
  • The last three reported values for Total Liabilities were $248.8 million (Q4 2025), $252.5 million (Q4 2024), and $249.6 million (Q4 2023) per Business Quant data.